Our observation that the N/Mef2 and N/Src synergies both activate the same pathway (JNK) but display differences in downstream phenotype suggests that it may be possible to identify targeted, refined signatures for different types of Notch, Src, and JNK-related cancers. This evidence concerns the gene MAPK8 and cancer.